Source: https://www.wipo.int/amc/en/domains/search/text.jsp?case=D2012-1900
Timestamp: 2019-04-25 15:45:59+00:00

Document:
The Respondent is Domains By Proxy, LLC / Daniel Kertzman of Scottsdale, Arizona, United States of America and Marina del Rey, California, United States of America, respectively.
The disputed domain name <valiumsale.com> is registered with GoDaddy.com, LLC (the “Registrar”).
The Complaint was filed with the WIPO Arbitration and Mediation Center (the”Center”) on September 25, 2012. On September 25, 2012, the Center transmitted by email to the Registrar a request for registrar verification in connection with the disputed domain name. On September 27, 2012, the Registrar transmitted by email to the Center its verification response disclosing registrant and contact information for the disputed domain name, which differed from the named Respondent and contact information in the Complaint. The Center sent an email communication to the Complainant on September 27, 2012, providing the registrant and contact information disclosed by the Registrar, and inviting the Complainant to submit an amendment to the Complaint. The Complainant filed an amendment to the Complaint on September 27, 2012.
In accordance with the Rules, paragraphs 2(a) and 4(a), the Center formally notified the Respondent of the Complaint, and the proceedings commenced on October 1, 2012. In accordance with the Rules, paragraph 5(a), the due date for Response was October 21, 2012. The Respondent did not submit any response. Accordingly, the Center notified the Respondent’s default on October 31, 2012.
The Center appointed David Williams as the sole panelist in this matter on November 21, 2012. The Panel finds that it was properly constituted. The Panel has submitted the Statement of Acceptance and Declaration of Impartiality and Independence, as required by the Center to ensure compliance with the Rules, paragraph 7.
The Complainant is a global research-focused healthcare company that operates worldwide in the fields of pharmaceuticals and diagnostics with operations in numerous countries worldwide. The VALIUM trademark designates a sedative and anxiolytic drug belonging to the benzodiazepine family. The VALIUM trademark is registered in favour of the Complainant in numerous countries around the world. The registrations include an international registration with a priority date of December 20, 1961.
The disputed domain name <valiumsale.com> was registered on September 18, 2012.
The Complainant contends that the disputed domain name is confusingly similar to the Complainant’s mark because it incorporates this mark in its entirety. The Complainant cites F. Hoffman-La Roche AG v. NetMarketing cc, WIPO Case No. D2005-1216, which concerned a similar domain name <valium-sale.com>. The mark VALIUM is well-known and notorious as supported by newspaper articles, copies of which have been provided to the Panel. The notoriety of the mark increases the likelihood of confusion.
The Complainant further contends that its use and registration of its mark predate the Respondent’s registration of the disputed domain name.
The Complainant has exclusive rights for the VALIUM mark. No consent was granted to the Respondent to use VALIUM in the disputed domain name. The Complainant alleges it is obvious that the Respondent uses the disputed domain name for commercial gain and with the purpose of capitalizing on the fame of the Complainant’s VALIUM mark. The Respondent’s website, to which the disputed domain name directs, is a “search engine” with sponsored links. The Complainant can see no reason why the Respondent should have any right or interest in this disputed domain name.
The Complainant further contends that the disputed domain name was registered in bad faith since at the time of the registration, on September 18, 2012, the Respondent was bound to have knowledge of the Complainant’s well-known product and VALIUM mark. The Complainant argues that the disputed domain name is being used in bad faith because when viewing the website at the disputed domain name, one realises that the Respondent is intentionally attempting (for commercial purposes) to attract Internet users to this website by causing confusion as to the source, affiliation and endorsement of the Respondent’s website, or the products or services posted on, or linked to, the Respondent’s website.
The use of the disputed domain name seems to be to display advertising links to websites promoting and/or offering products and services of third parties, especially in the pharmaceutical field, being the business of the Complainant. The Complainant alleges that, by using the disputed domain name, the Respondent is intentionally misleading the consumers and confusing them so as to attract them to other websites making them believe that the websites behind those links are associated with or recommended by the Complainant. As a result, the Complainant fears that the Respondent may generate unjustified revenues for each click-through by online consumers on the sponsored links. The Complainant claims that the Respondent is therefore illegitimately capitalising on the fame of the VALIUM mark.
The Respondent, having been duly notified of the Complaint and these proceedings, did not reply to the Complainant’s contentions or take any part in these proceedings.
In accordance with paragraph 14(a) of the Rules in the event that a Party, in the absence of exceptional circumstances, does not comply with any of the time periods established by the Rules or the Panel, the Panel shall proceed to a decision on the Complaint; and (b) if a Party, in the absence of exceptional circumstances, does not comply with any provision of, or requirement under the Rules, or any request from the Panel, the Panel shall draw such inferences as it considers appropriate.
The Panel must not decide in the Complainant’s favour solely based on the Respondent’s failure to reply to the Complainant’s contentions, see Cortefield, S.A. v. Miguel Garcia Quitas, WIPO Case No. D2000-0140). The Panel must decide whether the Complainant has introduced elements of proof, which allow the Panel to conclude that its allegations, on balance of the probabilities, have merit.
In order to transfer the disputed domain name to the Complainant, the Panel must be satisfied that with regard to this element: (a) the Complainant has rights in a trade mark or service mark; and (b) that the disputed domain name is identical or confusingly similar to that trade mark or service mark.
For the purposes of the Policy, the question of identity or confusing similarity requires a comparison of the disputed domain name and the Complainant’s trade mark rights, which have been proven. In this case, the disputed domain name has two differences from the Complainant’s VALIUM trade mark: the addition of the “.com” suffix and the addition of the word “sale” to the trademark. As the panel found in F. Hoffmann-La Roche AG v. George Stiegman, WIPO Case No. D2008-1572, when comparing the disputed domain name to VALIUM, “the addition of the generic top-level domain (gTLD) ‘.com’ is not legally significant since use of a gTLD is required of domain name registrants. The ‘.com’ gTLDs is one of several such gTLDs, and ’.com’ does not serve to identify a specific enterprise as a source of goods or services.” See also Ticketmaster Corporation v. DiscoverNet, Inc., WIPO Case No. D2001-0252, concerning the inclusion of a gTLD.
The fact that a domain name wholly incorporates a Complainant’s trademark has been found sufficient to establish identity or confusing similarity for the purpose of the Policy, despite the addition of other words to such marks. Many UDRP panels have found that the addition of words or letters to a mark used in a domain name does not generally alter the fact that the domain name is confusingly similar to the mark. The addition of a generic term does not serve to distinguish the domain name from the trademark. In this case, notwithstanding the gTLD, the disputed domain name consists of the Complainant’s VALIUM trade mark and the suffix “sale”. The Panel finds that the suffix “sale” is of a descriptive nature only, and the distinctive element of the disputed domain name is obviously the term “valium.” In these circumstances, the Panel concludes that Internet users finding the disputed domain name <valiumsale.com> are likely to be misled into believing that the Complainant is the registrant or is otherwise affiliated or associated with the disputed domain name. This was also found by the panel in F. Hoffmann-La Roche AG v. NetMarketing cc, WIPO Case No. D2005-1216. There the panel found the addition of the word “sale”, in that case with a hyphen to make a compound word, was descriptive and provides no distinctiveness or source of original elements whatsoever to the domain name at issue there, <valium-sale.com>.
In view of this, the Panel finds that the disputed domain name, registered by the Respondent, is identical or confusingly similar to the VALIUM trade mark, in which the Complainant has clearly demonstrated, to the satisfaction of the Panel, that it has well-established rights through registration and long, exclusive commercial use.
In the present case the Panel finds that the Complainant has established a prima facie case that the Respondent has no rights or legitimate interests in respect of the disputed domain name and the Respondent has failed to assert any such rights.
By declining to submit a Response, the Respondent has failed to invoke any circumstances, which could demonstrate any right or legitimate interest in the disputed domain name. The only evidence in this connection is that provided in the Complaint, and that which is self-evident from the website to which the disputed domain name refers.
The Complainant has exclusive rights to the VALIUM trade mark and has not licensed or otherwise permitted the Respondent to use its trade mark. Likewise, no evidence has been adduced that the Respondent has commonly been known by the disputed domain name; it is not making a legitimate noncommercial or fair use of the disputed domain name; nor has the Respondent been authorised or licensed by the Complainant to use the Complainant’s well-known VALIUM trade mark as part of the disputed domain name.
Furthermore, the Panel finds that the Respondent’s adoption of a domain name confusingly similar to the Complainant’s trademark inevitably leads to the diversion of the Complainant’s consumers to the Respondent’s website. In other words, the Respondent is, without justification, taking advantage of the good name and reputation of the Complainant and unfairly attempting to link to its own business and activities the substantial goodwill that the Complainant has established over many years in its registered marks.
Therefore, the Panel finds for the Complainant on the second element, that the Respondent has neither rights to nor legitimate interests in the disputed domain name.
The Panel finds that the VALIUM trade mark is well known in the field of pharmaceutical products. Therefore, the Respondent most likely knew of the Complainant, its products and trade marks prior to registering the disputed domain name. The Respondent registered the disputed domain name almost half a century after the Complainant registered its VALIUM trade mark. In view of the fame of the Complainant’s trade mark, there is no doubt that the Respondent was aware of the trade mark VALIUM prior to registering the disputed domain name. Indeed, in the Panel’s estimation, there could be no other reason for the Respondent’s registration of the disputed domain name other than to use it to direct Internet traffic to the Respondent’s website.
Consistent with the opinions of previous panels (see F. Hoffmann-La Roche AG v. George Stiegman, WIPO Case No. D2008-1572; and F. Hoffmann-La Roche TMNET, Anton Gorodov, WIPO Case No. D2008-0995), it seems indeed that by using the Complainant’s trademark in the disputed domain name, the Respondent has intentionally created a likelihood of confusion with the Complainant’s mark as to the source, sponsorship, affiliation or endorsement of the Respondent’s website.
The deliberate diversion of Internet users constitutes bad faith, by creating confusion that takes advantage of the Complainant’s goodwill. It is well established in prior UDRP decisions that such confusion, and the resultant misdirection of Internet traffic, is independently sufficient to establish bad faith. See e.g. Sony Ericsson Mobile Communications International AB, Telefonaktiebloaget LM Ericsson, Sony Corporation v. Party Night Inc., WIPO Case No. D2002-1128.
- The Complainant’s trademark VALIUM is an internationally well-known mark in the field of pharmaceuticals. See F. Hoffmann-la Roche AG v. Popo, WIPO Case No. D2008-0423; F. Hoffmann-La Roche AG v. TMNET, Anton Gorodov, WIPO Case No. D2008-0995; and F. Hoffmann-La Roche AG v. DNS Administrator/Turvill Consultants Ltd-RD, WIPO Case No. D2006-0047.
-The Respondent appears to be trading on the Complainant's goodwill and reputation, which the Complainant has built up over many years. This, without any explanations by the Respondent to the contrary, of which none have been forthcoming, constitutes bad faith. See e.g., eBay Inc. v. Sunho Hong, WIPO Case No. D2000-1633.
Furthermore, the failure of the Respondent to file any answer to the present Complaint or otherwise participate in the present proceedings, in the view of the Panel, also suggests bad faith on the part of the Respondent.
For all the reasons, the Panel concludes that the Respondent registered and is using the disputed domain name in bad faith.
For all the foregoing reasons, in accordance with paragraphs 4(i) of the Policy and 15 of the Rules, the Panel orders that the disputed domain name, <valiumsale.com> be transferred to the Complainant.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.